Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 117Active not recruiting 40Recruiting 29Terminated 28Withdrawn 9Not yet recruiting 3Unknown 2No longer available 2Enrolling by invitation 1

Sponsor Class

OTHER 61NETWORK 3INDUSTRY 2UNKNOWN 1OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma 1

Interventions

Injections 53Cisplatin 47Paclitaxel 46Carboplatin 41Gemcitabine 37Docetaxel 36Capecitabine 36pembrolizumab 35Drug Therapy 34anlotinib 25icotinib 23Fluorouracil 23Bevacizumab 23Cyclophosphamide 22Oxaliplatin 19fludarabine 18Pemetrexed 17Irinotecan 16Leucovorin 15Temozolomide 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Nivolumab 13Trastuzumab 11Rituximab 11Etoposide 11tesetaxel 10SHR-1701 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Lenalidomide × Clear all
NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Oncotherapeutics

Phase 1 Unknown
22 enrolled
Plasma cell

Multiple Myeloma

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Keymed Biosciences Co.Ltd

Phase 1 Unknown
87 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡